EMEA-000716-PIP01-09-M04
Key facts
| Invented name |
Mayzent
|
| Active substance |
Siponimod (hemifumarate)
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0119/2022
|
| PIP number |
EMEA-000716-PIP01-09-M04
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of multiple sclerosis
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Novartis Europharm Limited
|
| Decision type |
PM: decision on the application for modification of an agreed PIP
|